Copyright
©The Author(s) 2018.
World J Gastroenterol. May 7, 2018; 24(17): 1888-1900
Published online May 7, 2018. doi: 10.3748/wjg.v24.i17.1888
Published online May 7, 2018. doi: 10.3748/wjg.v24.i17.1888
Figure 3 Effect of plecanatide and dolcanatide on localization of occludin in epithelial cells.
Caco-2 (A) and T84 (B) cell monolayers were treated with 1 μmol/L plecanatide or dolcanatide in the presence or absence of 100 μg/mL of LPS for 16 h followed by immunofluorescence imaging for occludin. Representative microscopic fields demonstrate disruption of occludin localization by LPS. Co-treatment of LPS with plecanatide or dolcanatide preserved occludin localization around the cell membrane, as was observed for vehicle treated cells. Images taken at 40 × resolution. Blue fluorescence corresponds to DAPI stained nucleus. DAPI: 4’, 6’-diamidino-2-phenylindole; LPS: lipopolysaccharide.
- Citation: Boulete IM, Thadi A, Beaufrand C, Patwa V, Joshi A, Foss JA, Eddy EP, Eutamene H, Palejwala VA, Theodorou V, Shailubhai K. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models. World J Gastroenterol 2018; 24(17): 1888-1900
- URL: https://www.wjgnet.com/1007-9327/full/v24/i17/1888.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i17.1888